(DIR) Home
Personalised screening for women in early pregnancy could better
predict pre-eclampsia
(HTM) Source
----------------------------------------------------------------------
A new study compared guidelines for who is at risk for dangerous
hypertension during pregnancy with a personalised screening algorithm.
ADVERTISEMENT
Personalised screening early in pregnancy could help doctors better
predict who might be at risk for pre-eclampsia, according to a new
study.
The condition is a type of high blood pressure that can be dangerous
in pregnancy and is a leading cause of maternal death worldwide.
According to the UK's National Health Service (NHS), pre-eclampsia
affects two to five of every 100 pregnancies.
A new study of more than 7,000 women with first-time pregnancies
suggests that a screening algorithm that includes maternal history,
blood marker tests, and ultrasounds could help to identify a woman's
risk for pre-eclampsia in the first 13 weeks of pregnancy.
Researchers used the Fetal Medicine Foundation's (FMF) screening
algorithm and found that it detected pre-term pre-eclampsia in 63 per
cent of cases and early-onset pre-eclampsia in 77 per cent of cases.
The screening had a false positive rate of 15 per cent.
It was better at identifying risk than guidelines from the American
College of Obstetricians and Gynaecologists (ACOG), the researchers
said, which had equivalent detection rates of 62 per cent for pre-term
pre-eclampsia and 59 per cent for early-onset pre-eclampsia, with a
higher false positive rate of 34 per cent.
The ACOG guidelines recommend that pregnant women take aspirin if they
have a major risk factor for pre-eclampsia such as chronic high blood
pressure or type 2 diabetes or if they have two moderate risk factors.
## 'Easier to make the right decision'
Researchers say when using the FMF model, treatment can be based on an
individual's personal risk.
"With their personal risk calculated, it's much easier for a woman to
make the right decision, for example, if she chooses to take daily
low-dose aspirin, she is much more likely to follow through because
it's based on [a] personalised screening test," Emmanuel Bujold, a
senior study author and gynaecology professor at the Université Laval
in Canada, said in a statement.
Published in the journal **Hypertension** , the study was carried out
between 2014 and 2020 at five health centres in Canada.
Fewer than 1 per cent of the participants developed pre-term and
early-onset pre-eclampsia.
Sadiya Khan, an associate professor of medicine and preventive
medicine at Northwestern University in the United States, who was not
involved in the study, said in a statement that a screening model in
early pregnancy is "very helpful and can initiate conversations
between the clinician and patient about strategies to optimise heart
health".
"However, challenges remain with implementation of models such as this
one that integrate biomarkers that are not routinely assessed and may
not be widely available, especially among people in vulnerable
populations who are most likely to have the highest risk for preterm
preeclampsia," Khan said.
One of the study's limitations was that several women with risk
factors for pre-eclampsia were excluded from the research if they were
already taking aspirin. Previous studies have shown that taking one
low-dose aspirin daily can reduce the risk of pre-eclampsia.
The blood samples were also analysed in a single laboratory, so the
biomarkers were measured several weeks after the blood was drawn.
______________________________________________________________________
Served by Flask-Gopher/2.2.1